Swedish data also show that blood pressure control in hypertension is associated with a lower risk of newonset AF. 9 In most clinical practices AF patients are screened for thyroid disorders, but should we also introduce PA screening in this group? Mourtzinis et al. tried to address this question analysing a large Swedish database.
An indisputable merit of the present study is the robustness of analysed data -713,569 cases and 1,393,953 controls -large enough to detect differences in low prevalence rate conditions. Even in this case, however, there is a question about the validity and precision of data to test the working hypothesis.
The authors have clearly stated that the case cohort included all patients with a registered diagnosis of AF, but we know that AF may be asymptomatic in a sizeable proportion of occasions and that even symptomatic intermittent forms are difficult to detect. 10 All patients in the case cohort in the study by Mourtzinis et al. have a hospital-validated diagnosis of AF, but it is also possible that a considerable proportion of the controls have undiagnosed AF, given the mean age in this group (74 years).
Another thing that should be considered is a probable screening detection bias (the authors address this, too, in their Discussion). One of the possible explanations for the results in the aforementioned study is that patients with AF are examined more thoroughly and it is far more likely for them to receive a diagnosis of any kind compared with the general healthy population. For example, the authors admit that all AF patients are screened for thyroid disorders, which is not the case in the control group.
Diagnosing PA is another issue: on one hand, it is a difficult diagnosis; on the other hand, PA is more likely to be looked for in patients with hypertension -as a possible aetiological factor for secondary hypertension. As 30% of the case cohort and 12% of the controls have hypertension, the intuitive conclusion is that AF patients should have been screened for PA more often than controls. This raises the question about the actual prevalence of PA: are AF patients just better examined than the general population or is PA a risk factor for the development of AF and should we screen all our AF patients for PA?
The prevalence of hypertension in both groups raises concern about the quality of the data used in that study. The authors report a 12% incidence of Department of Cardiology, Acibadem City Clinic Cardiovascular Center -University Hospital, Bulgaria hypertension for the general population with a mean age of 74 years. These numbers are relatively lowalmost 50% lower compared to established prevalence numbers. 11 Obviously, as also admitted by the authors, hypertension was underdiagnosed in this study, and of course, we know that hypertension could be an aetiological factor for AF, 12 and it is usually a symptom of PA as well as of thyroid disorders. 13 Should this issue be neglected, and should we be comforted by the reassurance from the authors that had arterial hypertension been systematically underdiagnosed, this process should have affected both groups equally?
We consider that screening for PA in AF patients would bring little benefit in everyday clinical practice, hence the rarity of PA and the uncertain pathophysiological link between the two conditions. The data in the study from Mourtzinis et al., although interesting and robust, do not have the power to change the established current clinical practice.
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